Oncolytic Herpes Virus Cancer Therapy Vectors
Summary
USPTO published patent application US20260091069A1 for an oncolytic herpes simplex virus vector with dual transcriptional and translational control for cancer therapy. The vector incorporates modified ICP27 and ICP34.5 genes under CEA promoter and miRNA-124/143 control respectively, and includes a virus-expressed cytokine cassette encoding IL-12 and IL-15/IL-15RA. Inventors include William Wei-Guo Jia, Dmitry V. Chouljenko, and six others.
What changed
USPTO published patent application US20260091069A1 on April 2, 2026, covering herpes simplex virus vectors engineered with dual regulatory controls for cancer therapy. The application claims vectors with ICP27 and ICP34.5 genes under control of a CEA promoter and miRNA-124/143 respectively, incorporating a deletion of at least one terminal repeat long region copy and a cytokine cassette encoding IL-12 and IL-15/IL-15RA under CXCR4 promoter control. CPC classifications include A61K 35/763, A61P 35/00, and C12N 7/00.
Regulated entities face no immediate compliance obligations from this patent application publication. Pharmaceutical and biotechnology companies developing oncolytic virus therapies should review the claims for potential overlap with their own research programs. Patent application publications do not create binding obligations but may inform IP strategy and freedom-to-operate analyses.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TRANSCRIPTIONAL AND TRANSLATIONAL DUAL REGULATED ONCOLYTIC HERPES SIMPLEX VIRUS VECTORS
Application US20260091069A1 Kind: A1 Apr 02, 2026
Inventors
William Wei-Guo Jia, Dmitry V. Chouljenko, I-Fang Lee, Yanal M. Murad, Xiaohu Liu, Guoyu Liu, Xuexian Bu, Zahid Delwar, Jun Ding
Abstract
A herpes virus vector is provided with both transcriptional and translational control. Within various embodiments the herpes virus vector is based upon a modified herpes virus and has both ICP27 and ICP34.5 under control of a CEA promoter and miRNA-124/143, respectively, and deletion of at least one copy of terminal repeat long region is provided to increase safety without sacrificing efficacy. The herpes virus vector can also incorporate a virus-expressed cytokine cassette encoding IL-12, IL-15/IL-15RA under the control of CXCR4 promoter.
CPC Classifications
A61K 35/763 A61K 38/208 A61K 38/2086 A61P 35/00 C12N 7/00 C12N 2710/16032 C12N 2710/16071
Filing Date
2022-03-24
Application No.
18283654
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Biotech (C12N) publishes new changes.